Authors

Nirav N. Shah, MD, is an associate professor of medicine in the Division of Hematology and Oncology at Medical College of Wisconsin.

Latest:

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nirmish Singla, MD

Latest:

Oncology Fellow Stresses Integrity in the Lab and Clinic

Research forms the backbone of medical knowledge, and research integrity is a crucial responsibility of any scientist.

Nisha Bansal, MD

Latest:

Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian Cancer

Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

Nitika Thawani, MD

Latest:

Dr. Thawani on AEs With Radiation Versus COVID-19 Symptoms in Lung Cancer

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Nitin Jain, MD

Nitin Jain, MD, is a professor of medicine in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Dr Jain on Current Challenges in Defining Venetoclax Failure in CLL

Nitya A. Narayan, MD

Latest:

Medical Ethics in Pediatric Oncology

Everyone, at every level, is checking, rechecking, thinking, researching, asking questions, discussing, analyzing, and trying to help patients.

Nitya Narayan, MD

Latest:

Work-Life Balance of a Hem/Onc Fellow

I am a member of the cohort of 30-something single Indian women who were not lucky enough to snag the right guy during med school, and perhaps am not genetically engineered to be good at dating and studying simultaneously.

Nitya Nathwani, MD

Latest:

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

Nizar J. Bahlis, MD

Latest:

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Nizar M. Tamir, MD, FACP, The University of Texas MD Anderson Cancer Center

Nizar M. Tannir, MD, FACP

Latest:

Dr Tannir on Unmet Needs in the Treatment of Rare Kidney Tumors

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center

Latest:

Evolving Practice Patterns for Advanced Clear Cell Renal Cell Carcinoma

Nizar M. Tannir, MD, FACP, The University of Texas MD Anderson Cancer Center

Nizar M. Tannir, MD, FACP, University of Texas MD Anderson Center

Noa Biran, MD

Latest:

A New Era In Multiple Myeloma Treatment: Advances and Future Directions

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Noah D. Kauff, MD

Latest:

Dr. Kauff on Challenges in Treating Uterine Cancer

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

Noah Federman, MD

Latest:

Dr. Federman on Challenges With Treating AYA Patients With Sarcoma

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.

Noah S. Kornblum, MD

Latest:

Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

Noel Clarke, MBBS, Christie Hospital

Noelle Frey, MD, MSCE

Latest:

Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.